Lisata Therapeutics Acquires Marea Therapeutics in $225M Financing Deal
Lisata Therapeutics has acquired clinical-stage biotech company Marea Therapeutics and secured a private placement financing of approximately $225 million. The deal is structured as a stock-for-stock transaction, with Marea's equity converted into over 213 million shares of Lisata common stock on an as-converted basis. Private placement investors will receive around 151 million shares at roughly $1,491.37 per share. The acquisition aims to advance two key clinical programs—MAR001/005 and MAR002—through critical milestones in cardioendocrine diseases by the end of 2027. The financing was oversubscribed and included participation from major institutional investors such as RA Capital Management, Forbion, Third Rock Ventures, Alpha Wave, Perceptive Advisors, Sofinnova Investments, Omega Funds, Surveyor Capital (a Citadel company), Columbia Threadneedle Investments, Nantahala Capital, Affinity Asset Advisors, LLC, venBio, and Rock Springs Capital. Lisata's shares surged over 65% in early trading before settling around a 20% increase. The transaction is expected to significantly broaden Lisata’s focus on cardioendocrine disease treatments.
Topics: Biotech Clinical Trials Pharmaceuticals Private Equity